Selective inhibitors of nuclear export (SINE) in hematological malignancies

Experimental Hematology and Oncology

Volumn 4, Issue 1, 2015, Pages

  Das, Arundhati ^a   Wei, Guoqing ^b   Parikh, Kaushal ^a   Liu, Delong ^c  

^a WESTCHESTER MEDICAL CENTER   (United States)

^b ZHEJIANG UNIVERSITY   (China)

^c ZHENGZHOU UNIVERSITY   (China)

Author keywords

KPT 330; Selective inhibitor of nuclear export; SINE; Slinexor

Indexed keywords

ANTINEOPLASTIC AGENT; EXPORTIN 1; KPT 185; KPT 251; KPT 276; SELECTIVE INHIBITORS OF NUCLEAR EXPORT; SELINEXOR; UNCLASSIFIED DRUG;

ACUTE LYMPHOBLASTIC LEUKEMIA; ACUTE MYELOBLASTIC LEUKEMIA; ANTINEOPLASTIC ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; APOPTOSIS; CANCER CHEMOTHERAPY; CANCER INHIBITION; CARCINOGENESIS; CHRONIC LYMPHATIC LEUKEMIA; DRUG CYTOTOXICITY; DRUG STRUCTURE; HEMATOLOGIC MALIGNANCY; HUMAN; LYMPHOMA; MANTLE CELL LYMPHOMA; MULTIPLE MYELOMA; NONHODGKIN LYMPHOMA; NONHUMAN; PHASE 1 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; REVIEW;

EID: 84978024579     PISSN: None     EISSN: 21623619     Source Type: Journal    
DOI: 10.1186/s40164-015-0002-5     Document Type: Review

References (33)

1. Dong X, Biswas A, Suel KE, Jackson LK, Martinez R, Gu H, et al. Structural basis for leucine-rich nuclear export signal recognition by CRM1. Nature. 2009;458(7242):1136-41.
2. Fung HY, Chook YM. Atomic basis of CRM1-cargo recognition, release and inhibition. Semin Cancer Biol. 2014;27:52-61.
3. Parikh K, Cang S, Sekhri A, Liu D. Selective inhibitors of nuclear export (SINE)- a novel class of anti-cancer agents. J Hematol Oncol. 2014;7(1):78.
4. Miao L, Schulten K. Probing a structural model of the nuclear pore complex channel through molecular dynamics. Biophys J. 2010;98(8):1658-67.
5. Abraham SA, Holyoake TL. Redirecting traffic using the XPO1 police. Blood. 2013;122(17):2926-8.
6. Adachi Y, Yanagida M. Higher order chromosome structure is affected by cold-sensitive mutations in a Schizosaccharomyces pombe gene crm1+ which encodes a 115-kD protein preferentially localized in the nucleus and its periphery. J Cell Biol. 1989;108(4):1195-207.
7. Fornerod M, Ohno M, Yoshida M, Mattaj IW. CRM1 is an export receptor for leucine-rich nuclear export signals. Cell. 1997;90(6):1051-60.
8. Xu D, Grishin NV, Chook YM. NESdb: a database of NES-containing CRM1 cargoes. Mol Biol Cell. 2012;23(18):3673-6.
9. Petosa C, Schoehn G, Askjaer P, Bauer U, Moulin M, Steuerwald U, et al. Architecture of CRM1/Exportin1 suggests how cooperativity is achieved during formation of a nuclear export complex. Mol Cell. 2004;16(5):761-75.
10. Nobumori Y, Shouse GP, Fan L, Liu X. HEAT repeat 1 motif is required for B56gamma-containing protein phosphatase 2A (B56gamma-PP2A) holoenzyme assembly and tumor-suppressive function. J Biol Chem. 2012;287(14):11030-6.
11. Turner JG, Sullivan DM. CRM1-mediated nuclear export of proteins and drug resistance in cancer. Curr Med Chem. 2008;15(26):2648-55.
12. Lapalombella R, Sun Q, Williams K, Tangeman L, Jha S, Zhong Y, et al. Selective inhibitors of nuclear export show that CRM1/XPO1 is a target in chronic lymphocytic leukemia. Blood. 2012;120(23):4621-34.
13. Newlands ES, Rustin GJ, Brampton MH. Phase I trial of elactocin. Br J Cancer. 1996;74(4):648-9.
14. Gravina G, Tortoreto M, Mancini A, Addis A, Di Cesare E, Lenzi A, et al. XPO1/CRM1-selective inhibitors of nuclear export (SINE) reduce tumor spreading and improve overall survival in preclinical models of prostate cancer (PCa). J Hematol Oncol. 2014;7(1):46.
15. Gerecitano J. SINE (selective inhibitor of nuclear export) - translational science in a new class of anti-cancer agents. J Hematol Oncol. 2014;7(1):67.
16. Saha M, Qiu L, Chang H. Targeting p53 by small molecules in hematological malignancies. J Hematol Oncol. 2013;6(1):23.
17. Foran JM. New prognostic markers in acute myeloid leukemia: perspective from the clinic. Hematology Am Soc Hematol Educ Program. 2010;2010:47-55.
18. Takahashi S. Current findings for recurring mutations in acute myeloid leukemia. J Hematol Oncol. 2011;4(1):36.
19. Loghavi S, Zuo Z, Ravandi F, Kantarjian H, Bueso-Ramos C, Zhang L, et al. Clinical features of De Novo acute myeloid leukemia with concurrent DNMT3A, FLT3 and NPM1 mutations. J Hematol Oncol. 2014;7(1):74.
20. Pastore F, Kling D, Hoster E, Dufour A, Konstandin N, Schneider S, et al. Long-term follow-up of cytogenetically normal CEBPA-mutated AML. J Hematol Oncol. 2014;7(1):55.
21. Luo J, Qi C, Xu W, Kamel-Reid S, Brandwein J, Chang H. Cytoplasmic expression of nucleophosmin accurately predicts mutation in the nucleophosmin gene in patients with acute myeloid leukemia and normal karyotype. Am J Clin Pathol. 2010;133(1):34-40.
22. Ranganathan P, Yu X, Na C, Santhanam R, Shacham S, Kauffman M, et al. Preclinical activity of a novel CRM1 inhibitor in acute myeloid leukemia. Blood. 2012;120(9):1765-73.
23. Kojima K, Kornblau SM, Ruvolo V, Dilip A, Duvvuri S, Davis RE, et al. Prognostic impact and targeting of CRM1 in acute myeloid leukemia. Blood. 2013;121(20):4166-74.
24. Etchin J, Sanda T, Mansour MR, Kentsis A, Montero J, Le BT, et al. KPT-330 inhibitor of CRM1 (XPO1)-mediated nuclear export has selective anti-leukaemic activity in preclinical models of T-cell acute lymphoblastic leukaemia and acute myeloid leukaemia. Br J Haematol. 2013;161(1):117-27.
25. Walker CJ, Oaks JJ, Santhanam R, Neviani P, Harb JG, Ferenchak G, et al. Preclinical and clinical efficacy of XPO1/CRM1 inhibition by the karyopherin inhibitor KPT-330 in Ph+ leukemias. Blood. 2013;122(17):3034-44.
26. Tai YT, Landesman Y, Acharya C, Calle Y, Zhong MY, Cea M, et al. CRM1 inhibition induces tumor cell cytotoxicity and impairs osteoclastogenesis in multiple myeloma: molecular mechanisms and therapeutic implications. Leukemia. 2014;28(1):155-65.
27. Schmidt J, Braggio E, Kortuem KM, Egan JB, Zhu YX, Xin CS, et al. Genome-wide studies in multiple myeloma identify XPO1/CRM1 as a critical target validated using the selective nuclear export inhibitor KPT-276. Leukemia. 2013;27(12):2357-65.
28. Azmi AS, Al-Katib A, Aboukameel A, McCauley D, Kauffman M, Shacham S, et al. Selective inhibitors of nuclear export for the treatment of non-Hodgkin's lymphomas. Haematologica. 2013;98(7):1098-106.
29. Yoshimura M, Ishizawa J, Ruvolo V, Dilip A, Quintas-Cardama A, McDonnell TJ, et al. Induction of p53-mediated transcription and apoptosis by exportin-1 (XPO1) inhibition in mantle cell lymphoma. Cancer Sci. 2014;105(7):795-801.
30. Zhang K, Wang M, Tamayo AT, Shacham S, Kauffman M, Lee J, et al. Novel selective inhibitors of nuclear export CRM1 antagonists for therapy in mantle cell lymphoma. Exp Hematol. 2013;41(1):67-78. e64.
31. London CA, Bernabe LF, Barnard S, Kisseberth WC, Borgatti A, Henson M, et al. Preclinical evaluation of the novel, orally bioavailable Selective Inhibitor of Nuclear Export (SINE) KPT-335 in spontaneous canine cancer: results of a phase I study. PLoS One. 2014;9(2):e87585.
32. Gutierrez M, Goy A, Byrd JC, Flynn JM, Sorensen M, Brown P, et al. A phase 1 dose-escalation study of the oral selective inhibitor of nuclear export (SINE) KPT-330 (selinexor) in patients (pts) with heavily pretreated non-Hodgkin lymphoma (NHL). ASCO Meeting Abstracts. 2014;32(15):8518.
33. Gravina G, Senapedis W, McCauley D, Baloglu E, Shacham S, Festuccia C. Nucleo-cytoplasmic transport as a therapeutic target of cancer. J Hematol Oncol. 2014;7(1):85.